Dozens of patients sue GLP-1 drugmakers over alleged vision loss
Dozens of patients have filed lawsuits against Novo Nordisk and Eli Lilly, claiming GLP-1 drugs like Ozempic and Mounjaro caused NAION, a rare eye condition that can lead to permanent vision loss. Novo Nordisk says the lawsuits lack merit and cites a company-funded study finding no increased NAION risk. The FDA has been investigating the link since 2024, and the US has not added warnings to GLP-1 medications.
9
Divergence score
2 outlets covered it, splitting into 2 framing camps across 2 bias groups.
2 camps
2 bias groups
Market signalBETA
The spectrum · how 2 outlets placed this story
LeftCenterRight
Al Jazeera
The Hill
Supportive of action
Neutral
Dismissive
Critical
Alarmist
International angle
Widest split · the two outlets furthest apart, and who published first
First to report
- Al Jazeerafirst
- The Hill+42 min
By each outlet's earliest publish time in this story. Feeds that index slowly can appear later than they printed.
The split, in one line
Al Jazeera provides extensive scientific context and regulatory detail, while The Hill offers a brief wire-style summary focused on patient allegations.
How each outlet covered it
No left-right split here
Coverage clusters in the center and international press. Here is each take as it stands.
Center & international coverage
“Dozens of people sue GLP-1 drug companies over alleged vision loss”
“Patients sue GLP-1 makers over sudden loss of vision”
8 tracked claims across 2 outlets
Fact ledger
All8Claimed3Corroborated5
1/2
Claimed
A Novo Nordisk-funded study found no increased risk of NAION from GLP-1 drugs
Corroborated
Disputed
7 more tracked claimsSign up free to see the full ledger